Walleye Capital’s Sage Therapeutics SAGE Stock Holding History

Walleye Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,800	Closed	-$30.4K	–	5792
2024 Q2	$30.4K	Buy	+2,800	New	+$35.9K	﹤0.01%	5044
2024 Q1	–	Sell	-20,200	Closed	-$438K	–	5836
2023 Q4	$438K	Buy	20,200 +12,900	+177%	+$256K	﹤0.01%	3052
2023 Q3	$150K	Sell	7,300 -5,100	-41%	-$147K	﹤0.01%	3734
2023 Q2	$583K	Buy	+12,400	New	+$617K	﹤0.01%	2314
2023 Q1	–	Sell	-3,200	Closed	-$122K	–	4302
2022 Q4	$122K	Sell	3,200 -2,400	-43%	-$91.7K	﹤0.01%	2296
2022 Q3	$219K	Buy	+5,600	New	+$216K	﹤0.01%	2048
2019 Q4	–	Sell	-20,800	Closed	-$2.92M	–	2205
2019 Q3	$2.92M	Buy	+20,800	New	+$3.48M	0.17%	134

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Walleye Capital's SAGE Position: Q3 2025 in Review

Walleye Capital sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 35,290 shares — an estimated $322K sold.

Walleye Capital first reported a position in SAGE in Q3 2019 and held it in 12 quarters. The position peaked at $3.22M in Q4 2021. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Walleye Capital reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Walleye Capital sold 35,290 Sage Therapeutics shares in Q3 2025, an estimated $322K.
Walleye Capital first reported a position in Sage Therapeutics in Q3 2019 and held it in 12 quarters.
Walleye Capital's Sage Therapeutics position peaked at $3.22M in Q4 2021.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Walleye Capital's 13F filing for Q3 2025, filed 14 Nov 2025.